Hcv Management VIII

Venture Capital Exempt reporting adviser

Legal name: Hcv Management VIII, LLC

Cambridge, MA Website

AUM

$5.1M
Private fund assets

Private funds

2
Venture Capital 2

Private fund assets

$5.1M
Gross asset value

Employees

—

Last Form D raise

—

From SEC Form ADV filing (filed Mar 9, 2026). View on SEC

People(6)

Owners and executive officers named on the firm's SEC Form ADV.

A
Augustine Lawlor
Member
Source: SEC Form ADV
C
Christopher Mirabelli
Member
Source: SEC Form ADV
H
Harold Werner
Member
Source: SEC Form ADV
J
James Cavanaugh
Member
Source: SEC Form ADV
J
John Littlechild
Member
Source: SEC Form ADV
M
Marla McMillan
Vice President of Finance
Source: SEC Form ADV

Funds(2)

Private funds reported on Form ADV, with amounts raised from the funds' SEC Form D filings.

FundTypeGross assetsRaised (Form D)InvestorsLast Form DRecency
Healthcare Ventures VIII, L.P.Venture Capital$5.1M———
Healthcare Ventures IX, L.P.Venture Capital————

Board seats(5)

Companies whose SEC Form D filings name one of this firm's people as a director, matched by name and office ZIP code.

Leap Therapeutics
PharmaceuticalsCambridge, MADirector: John Littlechild
$95.2M raised
Since Nov 2017
SEC Form D
Leap Therapeutics
PharmaceuticalsCambridge, MADirector: James Cavanaugh
$95.2M raised
Since Nov 2017
SEC Form D
Leap Therapeutics
PharmaceuticalsCambridge, MADirector: Christopher Mirabelli
$95.2M raised
Since Nov 2017
SEC Form D
GITR
BiotechnologyCambridge, MADirector: Augustine Lawlor
$2.8M raised
Since Jan 2012
SEC Form D
Theraclone Sciences
BiotechnologySeattle, WADirector: Christopher Mirabelli
$3.1M raised
Since May 2015
SEC Form D

Regulatory identifiers

CRD number
163510
SEC file number
802-75771

Sources